Patients usually present with a range of symptoms and signs ranging from pain to a liver mass that is detected during the evaluation of some other clinical condition.

Serum tumor markers do not have an important role in the evaluation or diagnosis of FL-HCC and are elevated in less than one-tenth of the patient population.